AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease

  • AIM ImmunoTech Inc AIM submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen.
  • The application is for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-onset COVID-19.
  • Related Link: AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients.
  • Intravenous therapy trial will assess 200 mg of Ampligen or placebo, with five doses over a treatment period of 17 days.
  • Intranasal therapy study will evaluate 1,250 μg spray (625 μg per nostril), with seven doses over a treatment period of 15 days.
  • In addition to studying efficacy and safety, the new Phase 2 protocols include exploratory endpoints that the company believes could support its recently filed provisional patent application.
  • Ampligen demonstrated a 100% protective survival benefit compared to 100% mortality in a saline control group in animal studies. 
  • Ampligen also reduced SARS-CoV-1 lung titers to below the level of detection.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: AIM stock is 1% at $1.99 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsCOVID-19 CoronavirusPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!